TRYPF - Tryp Therapeutics Explores Psilocybin's Potential In New Trials To Treat IBS And Fibromyalgia | Benzinga
Psychedelics biotech Tryp Therapeutics (OTCQB: TRYPF) is advancing its psilocybin-based portfolio through several recent milestones.
Upcoming Phase 1 For IV Psilocin
First, the company received approval from the Australian Human Research Ethics Committee (HREC) for a Phase 1 study on its IV-infused psilocin, TRP-8803. To take place at the CMAX Phase 1 unit in Adelaide, Australia, the open-label study will assess the safety and pharmacokinetics (PK) of a single intravenous (IV) infusion of the psychedelic in nine healthy adults.
On a broader scale, the trial is designed to determine the optimal blood levels of psilocin to achieve the targeted psychedelic state and, ultimately, provide "a major advance in psychedelic medicine” by optimizing the doses and infusion rates of IV-administered psilocin for targeted blood levels of psilocin.
The study will also collect real-time electroencephalogram (EEG) data from volunteers to monitor changes in EEG patterns associated with the psychedelic state, providing "invaluable” and believed-to-be first-in-class insights into the correlation between psilocin levels and the depth and duration of the psychedelic experience.
Tryp’s CSO Dr. Jim ...